US approvals for RESORBA suture range

RNS Number : 4612E

Advanced Medical Solutions Grp PLC

04 November 2015

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

510(k) Premarket notifications to market sutures in the US

Winsford, UK, 4 November 2015 - Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announces that it has received notice of further  Premarket 510(k) approvals, successfully adding to its first US suture approval from early 2015, thereby covering the vast majority of the rest of the suture product portfolio. With only one more suture type still awaiting US market approval, the Group is now well positioned to launch a comprehensive range of sutures into the US in mid 2016 through a combination of its branded and unbranded routes to market.

Chris Meredith, Chief Executive Officer of Advanced Medical Solutions, said: "We are pleased that we are now in a position to access the US surgical suture market which is estimated to be in excess of $1billion in size and dominated by a few major brands. This continues our strategy of extending our portfolio into new markets and gaining US approval for the RESORBA^® product range has been a strategic target of the Group since we acquired the business late 2011. The most recent approvals provide a new, significant opportunity for the Group."

- Ends -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director
Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan

About Advanced Medical Solutions Group plc - see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal^®, LiquiBand^® and RESORBA^® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 470 employees.  For more information please see www.admedsol.com.

 

END

 

 

MSCDMMGMZFGGKZZ